$1.56
-0.07 (-4.29%)
Open$1.59
Previous Close$1.63
Day High$1.65
Day Low$1.55
52W High$16.00
52W Low$1.40
Volume—
Avg Volume318.5K
Market Cap40.91M
P/E Ratio—
EPS$-2.18
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,953.8% upside
Current
$1.56
$1.56
Target
$32.04
$32.04
$22.50
$32.04 avg
$35.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |
| Rev Growth | +12.6% | +22.6% | -0.7% |
| Debt/Equity | 0.19 | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |